Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070845 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
A Phase 2 study of Primary Immune Thrombocytopenia, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT05070845: Recruiting Phase 2 study of Primary Immune Thrombocytopenia, sponsored by Pfizer.
NCT05070845 is a Phase 2 study of Primary Immune Thrombocytopenia that is actively recruiting participants, run by Pfizer. The registered enrollment target is 61 participants, below the 124-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05070845, a Phase 2 study of Primary Immune Thrombocytopenia, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
Primary Outcome
To evaluate absolute value of platelet count of treated participants
Conditions Studied
Interventions
- BIOLOGICAL PF-06835375
Study Locations (20)
Other
- Fakultni nemocnice Hradec Kralove - Hradec Králové
- Vseobecna fakultni nemocnice v Praze - Prague
- Semmelweis University - Budapest
- Petz Aladár Egyetemi Oktató Kórház - Győr
- Komárom-Esztergom Vármegyei Szent Borbála Kórház - Tatabánya
- InterHem - Bialystok
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne - Gdansk
- Pratia Onkologia Katowice - Katowice
New South Wales
- South West Radiology - Liverpool
- Slade Pharmacy - Mount Kuring-Gai
- Calvary Mater Newcastle - Waratah
North Carolina
- East Carolina University - Greenville
South Australia
- ICON Cancer Centre - Kurralta Park - Kurralta Park
Victoria
- The Alfred Hospital - Melbourne
Western Australia
- Royal Perth Hospital - Perth
Ontario
- Unity Health Toronto, St. Michael's Hospital - Toronto
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
What NCT05070845 shows while recruiting
NCT05070845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 124-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which PF-06835375 is the first listed.
NCT05070845 names 20 study sites across 11 states, led by Other, New South Wales, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05070845 about?
NCT05070845 is a clinical study titled "Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia". This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
What is the current status of trial NCT05070845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2022-02-02. Estimated completion is 2027-10-01.
What conditions does trial NCT05070845 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia.
What interventions are being tested in trial NCT05070845?
The interventions under investigation include: PF-06835375 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05070845?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05070845 being conducted?
This trial has 20 study locations across North Carolina, New South Wales, South Australia, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
COMPLETED · Phase 2
-
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
- NCT05593653 · 61 participants · Phase 4
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI